Core Viewpoint - TE HEALTHCARE has entered into a conditional acquisition agreement to purchase 100% of the shares of Top Eminent II Limited for HKD 100.3 million, which will integrate the financial performance of the acquired entity into the group's consolidated financial statements [1]. Group 1: Acquisition Details - The acquisition agreement was signed on February 26, 2026, with Top Eminent I Limited as the seller [1]. - The target company, Top Eminent II Limited, is an investment holding company registered in the British Virgin Islands in 2015 [3]. - The acquisition will result in the target company becoming an indirect subsidiary of TE HEALTHCARE [2]. Group 2: Business Operations - The target group primarily engages in cross-border e-commerce, focusing on online sales and distribution of health and wellness products in Hong Kong and China [3]. - The group also operates internet medical services and internet hospitals in China, providing online medical consultations and related value-added health management services [3]. - The foreign-owned enterprise, Shenzhen Beijing Tongrentang International Network Technology Co., Ltd., is a wholly-owned subsidiary of the Hong Kong company and is responsible for executing the contractual arrangements with the combined entities [2].

Core Viewpoint - The company is advancing its "online + offline" integrated internet medical service system to enhance patient experience through AI-enabled diagnostic and treatment scenarios [1] Group 1: Company Initiatives - The company is implementing online services such as appointment scheduling, payment, report inquiries, online consultations, and smart companion services [1] - AI applications for intelligent report interpretation and medical assistance have been launched in the company's hospitals, marking a significant upgrade in smart service and precision medicine [1] Group 2: Strategic Focus - The company aims to deepen its "medical + pharmaceutical" dual-driven strategy while further refining its business layout and enhancing health technology capabilities [1]

Core Viewpoint - The "Shanxi Medical University First Hospital Internet Hospital" has been approved to provide online services during the Spring Festival, ensuring public health support and convenience for patients [1] Group 1: Online Services - The internet hospital offers online consultations for common and chronic diseases, allowing patients to communicate with experts via mobile devices, thus saving time and enhancing family gatherings [1] - The "AI Smart Triage" feature is available 24/7, providing intelligent referral services where patients can describe symptoms and receive recommended departments for appointments [1] - The "Smart Pre-Consultation" function helps patients organize their medical conditions in advance, improving the efficiency of face-to-face consultations [1] Group 2: Family Support Features - During the Spring Festival, the internet hospital allows users to bind family members' information for various services, including appointment scheduling, online prescriptions, and payment of medical fees [1] - Services such as inpatient registration, appointment fee recharge, and report inquiries can also be handled on behalf of family members [1]

Core Insights - The Chinese dental healthcare industry is undergoing a critical transformation towards high-quality development, characterized by a resonance between supply and demand, and rapid growth [1][15]. Industry Overview - The dental healthcare industry focuses on oral health services, encompassing three main segments: diagnosis and treatment, care, and equipment [8]. - The service models include traditional public healthcare, specialized private operations, and emerging "Internet + dental healthcare" remote services, forming a multi-layered service system [12]. Market Dynamics - The industry has entered a mature phase over the past decade, with widespread application of digital and intelligent technologies, and continuous improvement in regulatory standards [14]. - The market size is expected to exceed 100 billion yuan by 2024, with a compound annual growth rate (CAGR) of over 15%, driven by significant growth in the dental treatment segment, particularly in dental implants and orthodontics [1][25]. Competitive Landscape - The industry is witnessing an increasing concentration trend, with leading companies leveraging capital, technology, and brand advantages to secure market positions [2]. - Emerging companies are focusing on digitalization and internet healthcare for innovative development, while foreign enterprises are investing in high-end equipment and services [2][39]. Consumer Demand - There is a notable shift in consumer demand from basic treatment to prevention, health maintenance, and aesthetic restoration, influenced by rising awareness of oral health [2][32]. - Key factors affecting purchasing decisions include brand reputation, medical technology, equipment quality, pricing, and payment methods [2]. Technological Advancements - Technological development is a core driver of the industry, with the widespread use of digital diagnostic equipment, 3D printing, and dental implant technologies [2]. - Information technologies such as telemedicine, big data, and artificial intelligence are enhancing diagnostic accuracy and efficiency, improving patient experiences [2]. Policy Environment - The government has introduced multiple policies to support the industry, including expanding insurance coverage for dental services and encouraging the development of private institutions [18][19]. - Local governments are implementing differentiated support policies, including special funds for infrastructure improvement and talent recruitment [21][22]. Market Growth Factors - The aging population is increasing the prevalence of dental diseases, leading to higher demand for dental restoration and implant services [31]. - Rising health awareness among residents is shifting demand towards preventive care and aesthetic services, driving market growth [32]. Industry Structure - The dental healthcare market comprises various participants, including large chain dental institutions, specialized dental hospitals, private clinics, and dental equipment manufacturers [28]. - The market structure is becoming more diversified and professionalized, with ongoing technological advancements and consumer upgrades [28].

Industry Overview - The pharmaceutical and biotechnology sector increased by 0.14% this week, ranking 15th among 31 primary industries in the Shenwan index, outperforming the CSI 300 index by 1.47 percentage points, which fell by 1.33% [2] - The medical services sub-sector reported a rise of 1.31%, while traditional Chinese medicine and medical commercial sectors also saw increases of 2.56% and 0.57%, respectively [2] Company Performance - Top-performing companies in the medical services sector included Meidisi (+18.0%), Tongce Medical (+8.1%), and NuoSiGe (+5.7%), while underperformers included Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3] - CXO-related companies experienced significant pullbacks [3] Valuation Metrics - The medical services sector's price-to-earnings (PE) ratio is currently at 34.43X, with a one-year maximum of 41.13X and a minimum of 28.46X; the price-to-book (PB) ratio stands at 3.49X, with a one-year maximum of 4.00X and a minimum of 2.48X [5] - The PE ratio increased by 0.56X and the PB ratio by 0.06X compared to the previous week [5] Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, focusing on pediatric specialties, which marks a significant regulatory advancement for internet healthcare in major cities [6] - This initiative is expected to enhance online medical services and provide new market opportunities for private healthcare providers [6] Investment Recommendations - The report maintains a "buy" rating for the medical services industry, suggesting a focus on high-growth areas such as ADC CDMO and weight-loss drug supply chains, as well as companies with improving profit expectations like Aier Eye Hospital and Dean Diagnostics [7] - The report emphasizes the importance of a multi-tiered payment system and the resilience of medical demand in stabilizing the industry [7]

Core Viewpoint - Southbound funds have significantly increased their holdings in Alibaba Health, indicating strong investor interest in the company [1] Group 1: Investment Activity - On February 11, southbound funds increased their holdings by 3.084 million shares of Alibaba Health (00241.HK) [1] - Over the past five trading days, there have been five days of net increases, totaling 30.328 million shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 132 million shares [1] - Currently, southbound funds hold 1.968 billion shares of Alibaba Health, representing 12.16% of the company's total issued ordinary shares [1] Group 2: Company Overview - Alibaba Health Information Technology Co., Ltd. provides industrial internet solutions for the medical and pharmaceutical industry [1] - The company is the flagship platform of Alibaba Group in the health sector, focusing on the development of pharmaceutical health product sales [1] - It operates a pharmaceutical e-commerce platform and consumer healthcare service platform, utilizing cloud computing and big data for traceability and digital healthcare [1]

Group 1 - The core idea of the articles emphasizes the importance of medical services during the Spring Festival, ensuring that healthcare remains accessible and responsive to the needs of the community [1][2][5] - Jiangsu's medical institutions are fully prepared for the holiday, providing continuous support for patients, especially vulnerable groups like cancer patients and pregnant women [2][3] - The "No Pain New Year" initiative by Jiangsu Provincial Cancer Hospital aims to provide compassionate care for cancer patients during the festive season, expanding its reach through a collaborative network of over 100 healthcare units [2][9] Group 2 - Online healthcare services are operational 24/7 during the Spring Festival, with hospitals like Nanjing Gulou Hospital offering telemedicine consultations and medication delivery to enhance patient convenience [4][5][6] - The integration of online and offline medical services ensures that patients can receive timely care, with emergency services available around the clock [6][8] - The establishment of specialized clinics, such as the fishbone clinic, addresses common holiday-related health issues, ensuring that patients have access to necessary treatments without delays [7][8] Group 3 - The use of drones for medication delivery in Dongtai City significantly improves access to essential medicines for elderly and chronic disease patients in rural areas, reducing their reliance on distant healthcare facilities [8][9] - The drone service operates efficiently, with an average of over 20 flights per day, ensuring timely delivery of medications and medical supplies to local health centers [9] - The implementation of personalized health plans in nursing homes, along with emergency preparedness measures, enhances the quality of care for elderly residents during the holiday season [10]

Core Viewpoint - JD Internet Hospital is launching the "New Year Health Guard" initiative to provide 24-hour online consultation services, integrating resources from top-tier hospitals to address health needs during the Spring Festival [1] Group 1: Service Overview - The initiative aims to alleviate healthcare access issues during the holiday season, ensuring timely and professional medical support for users [1] - Users can access the service through the JD APP by searching for "New Year Health Guard" or "Ask a Doctor," allowing for quick entry into the consultation channel [1] Group 2: User Experience - Previous experiences highlight the effectiveness of JD Internet Hospital's online consultation, such as a case where a user abroad received timely advice for a burn injury through video consultation with a top-tier hospital [3] - Another case involved a 71-year-old user who received a diagnosis and treatment plan for severe skin itching, demonstrating the platform's ability to provide effective medical guidance [3] Group 3: AI Integration - JD Health's AI doctor, "Dai Wei," operates around the clock, utilizing a self-developed medical model and comprehensive medical knowledge base to offer multi-round symptom collection, analysis, and recommendations [4] - The AI doctor integrates authoritative clinical guidelines and medical literature, providing evidence-based suggestions to enhance the quality of health services [4] Group 4: Strategic Goals - JD Health aims to leverage its internet medical service advantages and robust pharmaceutical supply chain capabilities to ensure quality medical resources are accessible regardless of users' locations [4] - The initiative seeks to provide peace of mind and health support for families during the reunion moments of the Spring Festival [4]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

Investment Rating - The report maintains a positive outlook on JD Health, indicating strong sales growth and a favorable investment environment [5][7]. Core Insights - JD Health is expected to maintain robust growth momentum in the second half of 2025, with revenue projected to increase year-on-year, driven by strong performance during the "Double 11" shopping festival and a surge in flu cases in December [5]. - The sales of pharmaceuticals and health products are particularly strong, with adjusted EBITDA expected to double due to margin expansion and operational leverage, offsetting investments in offline stores [5]. - The report highlights that JD Health's direct sales are anticipated to grow year-on-year in the second half of 2025, primarily driven by increased sales of pharmaceuticals and health products during the "Double 11" period [5][6]. Summary by Sections Company Overview - JD Health operates an online retail pharmacy business through self-operated and platform models, focusing on three core categories: pharmaceuticals (including prescription and OTC), health products, and medical devices [10]. Revenue Breakdown - Pharmaceuticals and health products account for 85.3% of revenue, while platform services, advertising, and other sources contribute 14.7% [11]. Market Position - As of February 4, 2026, JD Health's stock price is HKD 60.95, with a market capitalization of USD 26.24 billion and a consensus target price of HKD 76.85 [13].